Bismarck Hottor

Dr. Bismarck Hottor

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2024 in Anatomical Sciences Education
Verified
Journal Article
Closed access
BABenjamin Arko-Boham
Benjamin Arko-Boham
KAKofi Ampofo Abankwah
Kofi Ampofo Abankwah
KAKevin Kofi Adutwum-Ofosu
Kevin Kofi Adutwum-Ofosu
JAJOHN AHENKORAH
JOHN AHENKORAH
BHBismarck Hottor
Bismarck Hottor
NKNii Koney‐Kwaku Koney
Nii Koney‐Kwaku Koney

25 May 2021 in Medical Sciences
Verified
Journal Article
Open access
PDF file
EAEvelyn Adusei
Evelyn Adusei
JAJOHN AHENKORAH
JOHN AHENKORAH
NANii Armah Adu-Aryee
Nii Armah Adu-Aryee
KAKevin Kofi Adutwum-Ofosu
Kevin Kofi Adutwum-Ofosu
ETEmmanuel Ayitey Tagoe
Emmanuel Ayitey Tagoe
BABenjamin Arko-Boham
Benjamin Arko-Boham
Breast cancer is the most common malignancy in women, with alarming mortalities. Neoadjuvant treatments employ chemotherapy to shrink tumours to a well-defined size for a better surgical outcome. The current means of assessing effectiveness of chemotherapy management are imprecise. We previously showed that breast cancer patients have higher serum circulating cell-free DNA concentrations. cfDNA is degraded cellular DNA fragments released into the bloodstream. We further report on the utility of cfDNA in assessing the response to chemotherapy and its potential as a monitoring biomarker. A total of 32 newly diagnosed and treatment-naive female breast cancer patients and 32 healthy females as controls were included. Anthropometric, demographic and clinicopathological information of participants were recorded. Each participant donated 5 mL of venous blood from which sera were separated. Blood sampling was carried out before the commencement of chemotherapy (timepoint 1) and after the third cycle of chemotherapy (timepoint 2). qPCR was performed on the sera to quantify ALU 115 and 247 levels, and DNA integrity (ALU247/ALU115) was determined. ALU 115 and 247 levels were elevated in cancer patients but were significantly decreased after the third cycle of chemotherapy (T2) compared to T1. DNA integrity increased after the third cycle. Serum cfDNA may provide a relatively inexpensive and minimally invasive procedure to evaluate the response to chemotherapy in breast cancer.

26 July 2025 in Colorectal Cancer
Verified
Journal Article
Open access
BABernice Nana Akua Asaku
Bernice Nana Akua Asaku
BABenjamin Arko-Boham
Benjamin Arko-Boham
SQSolomon Edward Quayson
Solomon Edward Quayson
AAAbdul Rashid Adams
Abdul Rashid Adams
AHAndrew Hooper
Andrew Hooper
NKNii Koney-Kwaku Koney
Nii Koney-Kwaku Koney